All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On January 10, 2022, the U.S. Food and Drug Administration (FDA) lifted the clinical hold across all trials investigating allogeneic chimeric antigen receptor (allo-CAR) T-cell therapies.1 The clinical hold was introduced in October 2021 after it was reported that one patient with pretreated stage IV follicular lymphoma showed evidence of a chromosomal abnormality after receiving ALLO-501A CAR T cells in the phase I/II ALPHA2 study (NCT04416984). However, investigators confirmed that this was unrelated to any alloCAR-T product or the manufacturing process and had no clinical significance. The abnormality was an isolated event and was not detected in any other patient treated with the same ALLO-501A lot.
Clinical trials within the alloCAR-T platform are due to resume with the phase II trial of ALLO-501A in relapsed/refractory large B-cell lymphoma, it is expected to commence in mid-year 2022 pending discussions with the FDA. The clinical hold affected five alloCAR T trials designed to treat non-Hodgkin lymphoma and R/R multiple myeloma.
Allo-CAR T cells are derived from induced pluripotent stem cells from healthy donors that are genetically modified using the transcription activator-like effector nucleases (TALEN) gene-editing technology.
Subscribe to get the best content related to multiple myeloma delivered to your inbox